Peter Sondermann
Amministratore Delegato presso TACALYX GmbH
Profilo
Peter Sondermann was the founder of SuppreMol GmbH, where he held the title of Chief Scientific Officer until his departure.
He is also the founder of TACALYX GmbH.
Prior to founding SuppreMol GmbH, he worked as Head-Process Biochemistry at Roche Glycart AG and as Group Leader-Structural Immunology at Max Planck Institute of Biochemistry.
Dr. Sondermann received his undergraduate and doctorate degrees from the University of Bielefeld.
Posizioni attive di Peter Sondermann
Società | Posizione | Inizio |
---|---|---|
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Amministratore Delegato | - |
Precedenti posizioni note di Peter Sondermann
Società | Posizione | Fine |
---|---|---|
SuppreMol GmbH
SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Fondatore | - |
Max Planck Institute of Biochemistry | Corporate Officer/Principal | - |
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Corporate Officer/Principal | - |
Formazione di Peter Sondermann
University of Bielefeld | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
SuppreMol GmbH
SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Health Technology |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Commercial Services |
- Borsa valori
- Insiders
- Peter Sondermann